Curasight is active in the pharmaceutical industry. The company specializes in research and development of various drug candidates. The product portfolio includes, for example, research and development within Positron Emission Tomography (PET) and related ancillary services. The business is operating with the largest presence within Scandinavia. Curasight is headquartered in Copenhagen.

Quotes for Curasight A/S

Right Now

+/-
-0.16
%
-1,33%
Latest
11.84
High
12.34
Low
11.68
Volume
2 932
Turnover (DKK)
34 404
Market Value (MDKK)
235,5
Time (Latest trade)
2023-01-30 11:55

Board

CEO

  • Ulrich Krasilnikoff

Chairperson of the Board

  • Per Falholt

Board

  • Andreas Kjær
  • Charlotte Vedel
  • Kirsten Drejer
  • Lars Trolle
  • Ulrich Krasilnikoff

Videos

Largest Owners

Name Capital % Votes % Date
Andreas Kjær 30,26 30,26 2021-12-31
UK Curacap ApS 20,01 20,01 2021-12-31
Carsten Haagen Nielsen 12,11 12,11 2021-12-31
Jacob Madsen 4,57 4,57 2021-12-31
Lars Trolle 2,96 2,96 2021-12-31
Per Falholt 0,33 0,33 2021-12-31
Charlotte Vedel 0,20 0,20 2021-12-31
Hanne Damgaard Jensen 0,18 0,18 2022-09-01
Milou Holding ApS 0,11 0,11 2021-09-20
Krasilnikoff Holding 1 Aps 0,04 0,04 2021-09-20
Holdings by Modular Finance AB. Compiled and processed data from various sources, including VP Securities, Morningstar and The Danish Financial Supervisory Authority (Finanstilsynet)

Insider trading

Key Numbers

*Compiled data from Millistream

Upcoming reports

  • 2023-02-23 Bokslutskommuniké 2022

  • 2023-03-30 Årsstämma 2022

  • 2023-05-25 Delårsrapport 2023-Q1

  • 2023-08-24 Delårsrapport 2023-Q2

  • 2023-11-24 Delårsrapport 2023-Q3